Instrument Inactif

Communiqués Baxalta Inc

Actions

US07177M1036

Cours en clôture Nyse Autres places de cotation
- ^USD	-

2016	Alcoa : Wall Street termine dans le désordre une séance volatile	RE
2016	Wall Street termine dans le désordre une séance volatile	RE

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Baxalta : Shire Completes Combination With Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions	03/06/16	PR
Baxalta : CORRECTING and REPLACING Baxalta Shareholders Vote to Approve Combination	27/05/16	BU
Baxalta : OncoResponse Secures Investment from Baxalta	26/05/16	BU
Baxalta : Reports Positive Phase 1 Results for BAX 930, Investigational Recombinant ADAMTS13 to Treat Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)	25/05/16	BU
Baxalta : Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.	25/05/16	BU
Baxalta : Announces Preliminary Merger Consideration Election Results	23/05/16	BU
Baxalta : Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE® (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer	19/05/16	PR
Baxalta : Declares Quarterly Dividend	10/05/16	BU
Baxalta : Baxter Increases the Size of Its Previously Announced Offer to Exchange Shares of Baxter for Shares of Baxalta	04/05/16	BU
Baxalta : Receives Positive Opinion from Europe’s CHMP for HYQVIA to Treat Pediatric Patients	02/05/16	BU
Baxalta : Exceeds Guidance and Delivers Strong Sales and Earnings for First Quarter 2016	28/04/16	BU
Baxalta : Baxter Initiates Offer to Exchange Shares of Baxter for Shares of Baxalta	21/04/16	BU
Baxalta : Supports Research to Raise Awareness of Treatment Burden on Patients during the Sixth Annual World Primary Immunodeficiency Week	21/04/16	BU
Baxalta : Announces Date for Special Meeting of Stockholders to Vote on Combination With Shire	14/04/16	BU
Baxalta : Expands Global Reach of ADYNOVATE for Hemophilia A Patients with Approval in Japan	04/04/16	BU
Baxalta : Announces Pricing of Secondary Offering of Common Stock	16/03/16	BU
Baxalta : Announces Secondary Offering of Common Stock	15/03/16	BU
Baxalta : Commences Phase 1 Clinical Trial of BAX 826, the Company’s Second Extended Half-Life Factor VIII Treatment for Hemophilia A	04/03/16	BU
Baxalta : to Showcase Innovation Leadership in Primary Immune Deficiencies During 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting	03/03/16	BU
Baxalta : Submits Marketing Authorization Application to the European Medicines Agency for ADYNOVI for Treatment of Hemophilia A Patients	02/03/16	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Baxalta Inc

Actions

US07177M1036

Communiqués

Filtres